179 related articles for article (PubMed ID: 36752816)
21. JAK protein kinase inhibitors.
Thompson JE
Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
[TBL] [Abstract][Full Text] [Related]
22. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
23. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
24. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
25. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
26. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
28. The Janus kinases (Jaks).
Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
[TBL] [Abstract][Full Text] [Related]
29. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
30. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
31. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
32. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
34. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
Qiu Q; Chi F; Zhou D; Xie Z; Liu Y; Wu H; Yin Z; Shi W; Qian H
J Med Chem; 2023 Apr; 66(8):5753-5773. PubMed ID: 37057760
[TBL] [Abstract][Full Text] [Related]
35. Progress on the Pharmacological Targeting of Janus Pseudokinases.
Henry SP; Jorgensen WL
J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
[TBL] [Abstract][Full Text] [Related]
36. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
Krishnan K; Pine R; Krolewski JJ
Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
[TBL] [Abstract][Full Text] [Related]
37. HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode.
Zhao L; Liang Q; He Y; Liu M; Tong R; Jiang Z; Wang W; Shi J
Bioorg Chem; 2022 Dec; 129():106181. PubMed ID: 36302332
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
Kato JY; Korenaga S; Iwakura M
Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
[TBL] [Abstract][Full Text] [Related]
39. Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock.
Gatsios P; Terstegen L; Schliess F; Häussinger D; Kerr IM; Heinrich PC; Graeve L
J Biol Chem; 1998 Sep; 273(36):22962-8. PubMed ID: 9722518
[TBL] [Abstract][Full Text] [Related]
40. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
